Biodesix Q3 revenue misses estimates on seasonality impact, project delays

By Reuters News


Overview

  • Diagnostic solutions firm's Q3 revenue grew 10% yr/yr but missed analyst expectations

  • Adjusted EBITDA loss improved 16% yr/yr as company reduced net loss

  • Company revised 2026 revenue guidance to $101 mln-$103 mln, reflecting Q3 results and project timing


Outlook

  • Biodesix expects 2026 revenue of $101 mln to $103 mln

  • Company anticipates maintaining gross margins of approximately 80% in 2026

  • Outlook reflects sales team expansion and timing of Development Services contract execution


Result Drivers

  • SALES TEAM SHORTFALL - Fewer contributing sales representatives than planned limited new physician and account growth, per CEO Scott Hutton

  • SEASONALITY IMPACT - Greater-than-anticipated seasonality, primarily in primary care, reduced ordering frequency among otherwise stable base customers, per CEO Scott Hutton

  • PROJECT DELAYS - Delays in external customer dependencies postponed the start of Development Services projects and associated revenue recognition, per CEO Scott Hutton


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$24.04 mln

$27.49 mln (7 Analysts)

Q3 Net Loss

$8.03 mln

Q3 Operating Expenses

$30.15 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for Biodesix Inc is $40.00, about 86.1% above its November 4 closing price of $21.49


Reuters Recommended Reads

  • Nov 4 - Adaptive Biotechnologies Q3 revenue falls 11% but beats estimates

  • Nov 4 - Bio-Rad's Q3 revenue comes slightly above estimates on Clinical Diagnostics growth

  • Nov 4 - Caris Life Sciences' Q3 revenue rises on molecular profiling strength


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk